VTGN

#4758
Vistagen Therapeutics, Inc. - Common Stock
0.2 4 USD
+0.04%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
0.24
0.24
Year Range
0.20
0.80
Daily Change
+4.35%
Monthly Change
+9.09%
6 month change
-53.41%
Year Change
-53.41%
Previous Close
0.2 4
Open
0.2 4
Low
0.2 4
High
0.2 4
Volume
14
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Vistagen Therapeutics, Inc. current report, Q2 FY2026
8-K

Vistagen Therapeutics, Inc. current report, Q2 FY2026

Business Context and Reporting Period

This Form 8-K Current Report was filed by Vistagen Therapeutics, Inc. on April 2, 2026, covering events occurring on April 1, 2026. The Company is a Nevada corporation with its principal executive offices in South San Francisco, California, and its common stock trades on the Nasdaq Capital Market under the symbol VTGN.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters rather than financial performance.

Material Changes

  • Audit Committee Composition: Effective April 1, 2026, Ms. Mary Rotunno resigned from the Board of Directors, reducing the Audit Committee membership from three to two.
  • Nasdaq Non-Compliance: The reduction in committee members resulted in non-compliance with Nasdaq Listing Rule 5605(c)(2), which mandates a minimum of three independent Audit Committee members.

Outlook, Risks, and Management Commentary

Listing Status: The Company's common stock listing on the Nasdaq Capital Market is not currently affected by this non-compliance.

Cure Period: Under Nasdaq Listing Rule 5605(c)(4)(B), the Company has been granted a cure period to regain compliance. This period expires on the earlier of the next annual meeting of stockholders or one year from the resignation date (April 1, 2027). If the annual meeting occurs within 180 days of the resignation, the cure period is limited to 180 days.

Management Plan: The Board has notified Nasdaq of its intent to regain compliance with the listing rule prior to the expiration of the cure period.

Investor Verification Checklist

  • Verify the timeline for the Company's next annual meeting of stockholders to determine the exact expiration date of the cure period.
  • Monitor future filings for the appointment of a new independent director to restore the Audit Committee to three members.
  • Review the March 18, 2026 Form 8-K for additional context regarding Ms. Rotunno's resignation.

News